Rewarding or aversive effects of buprenorphine/naloxone combination (Suboxone) depend on conditioning trial duration
Rewarding or aversive effects of buprenorphine/naloxone combination (Suboxone) depend on conditioning trial duration
复制标题
DOI：
10.1017/s146114571400025x
复制
发表时间：
2014-09-01
影响因子：
4.8
通讯作者：
Noble, Florence
中科院分区：
文献类型：
--
作者：
Canestrelli, Corinne;Marie, Nicolas;Noble, Florence
丁丙诺啡是治疗阿片类药物依赖的一种舌下药物。然而，它被静脉注射滥用。注射可能会限制其可接受性和传播。丁丙诺啡/纳洛酮(比例为4：1)已被开发出来，以减少转移和滥用。到目前为止，这种组合的相关性还没有在传统上用于研究滥用药物强化效应的动物模型中进行调查。本研究的目的是比较丁丙诺啡和丁丙诺啡/纳洛酮联合静注后条件位置偏爱(CPP)的奖赏效应。小鼠给药。动物分别给予不同剂量的丁丙诺啡或丁丙诺啡/纳洛酮(比例为4：1)，CPP条件反射试验时间为5或30min。在试验持续时间最长时，丁丙诺啡的量效曲线呈钟形，与纳洛酮合用后，量效曲线显著右移。在最短的试验持续时间内，丁丙诺啡/纳洛酮在动物体内观察到了涉及阿片受体样1(ORL1)的厌恶效应。这些发现可能解释了文献中报告的差异，因为一些作者表明，与丁丙诺啡相比，丁丙诺啡/纳洛酮的滥用在阿片类药物滥用者中有所减少，而另一些作者则没有。
Buprenorphine is used as a sublingual medication in the treatment of opioid dependence. However, its misuse by i.v. injection may limit its acceptability and dissemination. A buprenorphine/naloxone (ratio 4:1) combination has been developed to reduce diversion and abuse. So far, the relevance of this combination has not been investigated in the animal models traditionally used to study the reinforcing effects of drugs of abuse. The aim of this study was to compare the rewarding effects, assessed by conditioned place preference (CPP), of buprenorphine and buprenorphine/naloxone combination following i.v. administration in mice. Animals were treated with different doses of buprenorphine or buprenorphine/naloxone combination (ratio 4:1), and CPP conditioning trial duration was 5 or 30 min. At the longest trial duration, a bell-shaped dose-response curve was obtained with buprenorphine, which was shifted significantly to the right with naloxone combination. At the shortest trial duration, an aversive effect was observed with the buprenorphine/naloxone combination in animals, involving opioid receptor-like 1 (ORL1). These findings may explain the discrepancies reported in the literature as some authors have shown a reduced buprenorphine/naloxone misuse compared to buprenorphine in opioid abusers, while others have not.